Status:
UNKNOWN
Evaluation of Chemical Venous Thromboembolism Prophylaxis in Trauma
Lead Sponsor:
Methodist Health System
Conditions:
Thromboembolism, Venous
Eligibility:
All Genders
18-120 years
Brief Summary
Venous thromboembolism (VTE) causes up to 100,000 deaths annually. Between 10%-30% of patients die within one month of VTE diagnosis, while survivors remain at increased risk for VTE recurrence or oth...
Detailed Description
Trauma patients have many risk factors that predispose them to a VTE. During the first 48 hours after blunt trauma, patients are prothrombotic due to the release of procoagulant factors, have excessiv...
Eligibility Criteria
Inclusion
- ≥18 years of age
- Admitted to the trauma service between October 1,2021 and March 31, 2022
- Weight ≥50 kg
- Received chemical VTE prophylaxis with LMWH for at least 48 hours
- At "high risk" or "very high risk" of VTE8
Exclusion
- Death, discharge, or hospice within 48 hours of admission
- Documented heparin allergy (heparin-induced thrombocytopenia)
- Indication for therapeutic anticoagulation, either prior to admission or during hospitalization
- Prisoners
- \<18 years of age
- Pregnancy
Key Trial Info
Start Date :
July 21 2023
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
August 31 2024
Estimated Enrollment :
100 Patients enrolled
Trial Details
Trial ID
NCT06025162
Start Date
July 21 2023
End Date
August 31 2024
Last Update
September 6 2023
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Methodist Dallas Medical Center Pharmacy
Dallas, Texas, United States, 75203